XLON
PRM
Market cap5mUSD
Oct 09, Last price
1.36GBP
1D
-2.74%
1Q
-16.47%
Jan 2017
-74.18%
Name
Proteome Sciences PLC
Chart & performance
P/E
—
P/S
1.05
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-4.43%
Revenues
4m
-23.14%
Net income
-3m
L-10.13%
CFO
-46k
L-94.43%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Proteome Sciences Plc is a provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. It offers proprietary technologies for protein and peptide biomarker discovery, validation, and assay development. The company focuses on developing proprietary protein biomarkers for neurological diseases, oncology, and organ transplant rejection. Proteome Sciences was founded on December 10, 1993 and is headquartered in Cobham, the United Kingdom.
Key people
Geoffrey John Ellis
Finance Director, Company Secretary, Director · since 2014
Malcolm Ward
Chief Technical Officer - London Research Facility · since 2011
Ian H. Pike
Interim Chief Executive Officer, Chief Scientific Officer, Executive Director · since 2020
Glenn Barney
Vice President - Business Development, USA · since 2011
Richard Dennis
Chief Commercial Officer · since 2017
Josef Schwarz
Head - Projects & Production, Proteome Sciences R&D · since 2011
Gee See Chee
Director of Personalised Medicine
Christopher D. J. Pearce
Executive Chairman of the Board · since 2016
Non-Executive Director · since 2014
Non-Executive Director · since 2014
Headquarters & legal address
COVEHAM HOUSE
DOWNSIDE BRIDGE ROAD
COBHAM, SRY KT11 3EP
GB
DOWNSIDE BRIDGE ROAD
COBHAM, SRY KT11 3EP
GB
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||